 "Glenmark inks licensing pact with Polish firm Celon for inhaler")
Glenmark Pharmaceuticals Europe Ltd has entered into a strategic development & licensing agreement with Poland-based Celon Pharma SA to develop and market a generic version of GlaxoSmithKline’s Seretide Accuhaler product - fluticasone/salmeterol dry powder inhaler in Europe upon commercialisation.
As per the terms of the agreement, Glenmark has obtained semi-exclusive marketing & distribution rights of the product across 15 European countries including Great Britain, Germany, Belgium, the Netherlands, Italy, Sweden, Norway and Romania among others. Celon on the other hand, will receive an upfront payment, followed by certain milestone payments during various stages of the product’s development from Glenmark; including royalties on sales. The distribution agreement was concluded for a period of 10 years, with an option of a two-year extension.
“The deal reinforces Glenmark’s growing capabilities in the respiratory segment and is a significant step forward towards building a strong respiratory franchise in Europe. We are pleased to collaborate with Celon given their established track record with this inhaler product in Europe,” said Glenn Saldanha, chairman & MD, Glenmark Pharmaceuticals Limited.
Fluticasone/salmeterol dry powder inhaler is a combination product for the treatment of chronic obstructive pulmonary disease (COPD). Seretide marketed by GlaxoSmithKline is among the top 3 pharmaceutical brands in Europe with sales of $ 2.24 billion as per IMS.
Maciej Wieczorek, CEO of Celon Pharma SA, added, “For many years we have invested heavily in developing technologies for inhalation drugs, and this agreement is yet another proof that the direction we have chosen is correct. The common experiences of both companies in the area of manufacturing, commercialisation and distribution of inhaled drugs will translate into greater availability of combination therapy in a DPI inhaler in many European countries.”
As per the terms of the agreement, Glenmark has obtained semi-exclusive marketing & distribution rights of the product across 15 European countries including Great Britain, Germany, Belgium, the Netherlands, Italy, Sweden, Norway and Romania among others. Celon on the other hand, will receive an upfront payment, followed by certain milestone payments during various stages of the product’s development from Glenmark; including royalties on sales. The distribution agreement was concluded for a period of 10 years, with an option of a two-year extension.
“The deal reinforces Glenmark’s growing capabilities in the respiratory segment and is a significant step forward towards building a strong respiratory franchise in Europe. We are pleased to collaborate with Celon given their established track record with this inhaler product in Europe,” said Glenn Saldanha, chairman & MD, Glenmark Pharmaceuticals Limited.
Fluticasone/salmeterol dry powder inhaler is a combination product for the treatment of chronic obstructive pulmonary disease (COPD). Seretide marketed by GlaxoSmithKline is among the top 3 pharmaceutical brands in Europe with sales of $ 2.24 billion as per IMS.
Maciej Wieczorek, CEO of Celon Pharma SA, added, “For many years we have invested heavily in developing technologies for inhalation drugs, and this agreement is yet another proof that the direction we have chosen is correct. The common experiences of both companies in the area of manufacturing, commercialisation and distribution of inhaled drugs will translate into greater availability of combination therapy in a DPI inhaler in many European countries.”
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%